IBDASE

Mucosal protease and their inhibitors in inflammatory bowel disease: From etiopathogenetic insight to innovative therapy

Coordinatore	UNIVERSITAET BERN    more  Organization address address: Hochschulstrasse 4 city: BERN postcode: 3012 contact info Titolo: Dr. Nome: Daniel Cognome: Lottaz Email: send email Telefono: +41 31 632 1278 Fax: +41 31 632 0585
Nazionalità Coordinatore	Switzerland [CH]
Sito del progetto	http://www.ibdase.org/
Totale costo	4˙120˙034 €
EC contributo	2˙973˙550 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-FP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-03-01   -   2011-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITAET BERN  Organization address address: Hochschulstrasse 4 city: BERN postcode: 3012 contact info Titolo: Dr. Nome: Daniel Cognome: Lottaz Email: send email Telefono: +41 31 632 1278 Fax: +41 31 632 0585	CH (BERN)	coordinator	0.00
2	GOETEBORGS UNIVERSITET  Organization address address: VASAPARKEN city: GOETEBORG postcode: 405 30 contact info Titolo: Prof. Nome: Margareta Cognome: Ahlqwist Email: send email Telefono: +46 31 786 3488 Fax: +46 31 786 4355	SE (GOETEBORG)	participant	0.00
3	ISTITUTO EUROPEO DI ONCOLOGIA SRL  Organization address address: Via Filodrammatici 10 city: MILANO postcode: 20121 contact info Titolo: Ms. Nome: Ilaria Cognome: Foti Email: send email Telefono: +39 0 257489295 Fax: +39 02 94375991	IT (MILANO)	participant	0.00
4	JOHANNES GUTENBERG UNIVERSITAET MAINZ  Organization address address: SAARSTRASSE 21 city: MAINZ postcode: 55099 contact info Titolo: Dr. Nome: Karl Peter Christian Cognome: Spath Email: send email Telefono: +49 6131 3925891 Fax: +49 6131 3924741	DE (MAINZ)	participant	0.00
5	KATHOLIEKE UNIVERSITEIT LEUVEN  Organization address address: Oude Markt 13 city: LEUVEN postcode: 3000 contact info Titolo: Ms. Nome: Marion Cognome: Wolpers Email: send email Telefono: +32 16 326520 Fax: +32 16 326515	BE (LEUVEN)	participant	0.00
6	PROGENIKA BIOPHARMA SA  Organization address address: "Parque Tecnologico de Zamudio, Edificio 801 -A-, Planta 2" city: DERIO - VIZCAYA postcode: 48160 contact info Titolo: Dr. Nome: Gorka Cognome: Ramirez Email: send email Telefono: +34 944064525	ES (DERIO - VIZCAYA)	participant	0.00
7	SCIPROM SARL  Organization address address: RUE DU CENTRE 70 city: Saint-Sulpice postcode: 1025 contact info Titolo: Dr. Nome: Kirsten Cognome: Leufgen Email: send email Telefono: +41 21 69302 61	CH (Saint-Sulpice)	participant	0.00
8	UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA  Organization address address: VIA ORAZIO RAIMONDO 18 city: ROMA postcode: 173 contact info Titolo: Prof. Nome: Francesco Cognome: Pallone Email: send email Telefono: +39 0672596376 Fax: +39 0672596391	IT (ROMA)	participant	0.00
9	UNIVERSITE D'AUVERGNE CLERMONT-FERRAND 1  Organization address address: Boulevard Francois Mitterand 49 city: Clermont-Ferrand postcode: 63001 contact info Titolo: Dr. Nome: Laurent Cognome: Claret Email: send email Telefono: +33 04 73 17 83 76 Fax: +33 4 73 17 83 71	FR (Clermont-Ferrand)	participant	0.00
10	UNIVERSITY OF SOUTHAMPTON  Organization address address: Highfield city: SOUTHAMPTON postcode: SO17 1BJ contact info Titolo: Ms. Nome: Rachel Cognome: Green Email: send email Telefono: +44 23 8079 5081 Fax: +44 23 8079 5025	UK (SOUTHAMPTON)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'IBDase addresses the etiology and pathogenesis of inflammatory bowel disease (IBD) with a multidisciplinary plan for innovative diagnosis and therapy focused on mucosal proteases and their inhibitors (P/PIs). The incidence of IBD, a multifactorial disease influenced by environmental factors in a background of complex genetic susceptibility, is rising, particularly among European children. Current therapies lack efficacy and specificity. The gut microflora plays a crucial role in IBD but the cause for this is still poorly understood. Research implicating P/PIs in gut mucosal inflammation requires further mechanistic insight and the P/PIs relevant in human IBD need to be identified. To this end we will identify human mucosal P/PI polymorphisms affecting expression levels and/or activity of P/PIs and analyse their genotype/phenotype associations in IBD patient cohorts across Europe. IBD-associated P/PIs will be characterised by biochemical properties, expression in human clinical samples and manipulation of experimental models. Their interaction with microflora will be examined in animal models with controlled colonisation of the gut and in vitro co-culture models of intestinal mucosa and bacteria. In vivo studies will use targeted, well-established and new mouse models and evaluate zebrafish as an IBD model. Molecular mechanisms for involvement of IBD specific P/PI gene variants in the inflammatory response will be proposed. Therapeutics development will focus on specific inhibition or promotion of proteolysis in the intestinal mucosa, and select at least three validated P/PI of the intestinal mucosa for follow-up in clinical trials. Embracing the concept of tailoring treatment to individual patient characteristics to increase efficacy and reduce side-effects, IBDase strengthens international visibility of IBD related research, policies and industry and fosters IBD related research to the benefit of European society in both patient care and economic interest.'